Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The proposed study is an internet-based, randomized, double-blind, placebo-controlled trial
which will assess changes in hyperactivity in children ages five through eight with an autism
spectrum disorders (ASD) and elevated levels of hyperactivity. In order to answer this
question, this study will assess changes in hyperactivity as measured by the Aberrant
Behavior Checklist (ABC) in children with ASD and elevated baseline levels of hyperactivity
who are randomly assigned to use 1.3 grams of omega-3 fatty acids daily compared to placebo.
The overwhelming majority of study procedures, including recruitment, informed consent,
assessment of inclusion and exclusion criteria, and collection of baseline and outcome
measures will take place over the internet.
Phase:
Phase 2
Details
Lead Sponsor:
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.